Department of Ophthalmology, College of Medicine, King Saud University , Riyadh , Saudi Arabia.
Ocul Immunol Inflamm. 2013 Dec;21(6):468-74. doi: 10.3109/09273948.2013.779727. Epub 2013 Jun 4.
To assess long-term efficacy and safety of infliximab for refractory Behçet disease (BD) uveitis and to evaluate the effect of withdrawal of infliximab after achieving long-term remission.
Retrospective study of 19 patients.
Mean follow-up was 44.1 ± 36.5 months and mean number of infliximab infusions was 21.6 ± 14.6. At end of follow-up, there was significant improvement of visual acuity and reduction of central macular thickness. All patients achieved remission, 14 of whom were able to discontinue corticosteroids. Ten patients developed autoantibodies and 1 patient developed infusion reactions. Eight eyes underwent intraocular surgery without exacerbation of quiescent uveitis. After achieving complete remission, 5 patients discontinued infliximab and maintained remission during a mean of 24.6 ± 5.5 months.
Infliximab is effective and safe for long-term treatment for refractory BD uveitis. Repeated infusions are required to maintain long-term remission, which may be sustained despite withdrawal of infliximab. Induction of autoantibodies is common.
评估英夫利昔单抗治疗难治性贝赫切特病（BD）葡萄膜炎的长期疗效和安全性，并评估达到长期缓解后停用英夫利昔单抗的效果。
回顾性研究 19 例患者。
平均随访时间为 44.1 ± 36.5 个月，平均英夫利昔单抗输注次数为 21.6 ± 14.6。随访结束时，视力明显改善，中央黄斑厚度降低。所有患者均达到缓解，其中 14 例能够停用皮质类固醇。10 例患者出现自身抗体，1 例患者出现输注反应。8 只眼行眼内手术，静止性葡萄膜炎无加重。完全缓解后，5 例患者停用英夫利昔单抗，平均缓解 24.6 ± 5.5 个月。
英夫利昔单抗治疗难治性 BD 葡萄膜炎长期有效且安全。需要反复输注以维持长期缓解，尽管停用英夫利昔单抗，但缓解仍可持续。诱导自身抗体很常见。
